Keywords: Merck & Co, Isentress, HIV/AIDS, Pricing, AHF

Merck & Co “rewrites history” on pricing AIDS drug, Isentress, accuses AHF

Article | 25 January 2010

Print This

The controversy around US drug giant Merck & Co’s pricing for its key AIDS drug Isentress (raltegravir) - at ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in